However, the results of the HIV-1 vaccine clinical trial, RV144 in Thailand, showed 31.2% prevention of HIV-1 infection [7], revealed that the protection is caused mainly by the direct binding Abs to the first and second variable loops (V1/V2) and first conserved region (C1) of Env [8], [62]. This evidence concerns the gene ERVW-1 and HIV-1 infection.